Bioventus Agrees to Nationwide Contract with Cigna Commercial Plans for DUROLANE® and GELSYN-3® for Knee Osteoarthritis

Rhea-AI Summary

Bioventus (Nasdaq: BVS) has secured a nationwide contract with Cigna® effective July 1, 2022, offering access to its knee osteoarthritis treatments, DUROLANE and GELSYN-3. DUROLANE, a single-injection treatment, will be exclusive to Cigna patients, while GELSYN-3 will be among two multi-injection options available. Both products are hyaluronic acid-based therapies designed to alleviate knee OA pain, addressing the degeneration of joint tissues. Tim Donovan, Bioventus Vice President, expressed confidence in the therapeutic benefits of these products for Cigna members.

Positive

• Secured a nationwide contract with Cigna, expanding market access.
• DUROLANE offered exclusively to Cigna patients, enhancing product visibility.
• GELSYN-3 included as one of two multi-injection HA products under contract.
• Addresses a significant market need for knee osteoarthritis pain management.

Negative

• None.

DURHAM, N.C., May 02, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Cigna® commercial plans. Beginning July 1, 2022, Cigna® commercial plan members will have access to both DUROLANE and GELSYN-3, to treat knee osteoarthritis (OA) pain. DUROLANE, is a single-injection and GELSYN-3, is a three-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. Durolane will be exclusive to all Cigna patients while Gelsyn-3 will be one of two multi-injection HA products under contract.

OA involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues. Injection treatments of HA-based products, such as DUROLANE and GELSYN-3, help manage knee OA pain.

“We are pleased and excited DUROLANE and GELSYN-3 are among the preferred options available to Cigna® members and physicians,” said Tim Donovan, Vice President of Market Access & Health Economics for Bioventus. “Both now have access to two safe HA products that are proven to provide relief from knee OA pain.”

About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for pain treatment, restorative therapies and surgical solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com, and follow the Company on LinkedIn and Twitter. Bioventus, the Bioventus logo, GELSYN-3 and DUROLANE are registered trademarks of Bioventus LLC.

Media Contact:
Jamica Whitaker
Bioventus
919-666-5770
jamica.whitaker@bioventus.com

Investor Inquiries:
Dave Crawford
Bioventus
919-474-6787
dave.crawford@bioventus.com

FAQ

What new contract did Bioventus secure on May 2, 2022?

Bioventus secured a nationwide contract with Cigna for its knee osteoarthritis treatments DUROLANE and GELSYN-3.

When will Cigna members have access to DUROLANE and GELSYN-3?

Cigna members will have access to DUROLANE and GELSYN-3 starting July 1, 2022.

What are DUROLANE and GELSYN-3 used for?

DUROLANE and GELSYN-3 are hyaluronic acid-based treatments used to manage knee osteoarthritis pain.

What is unique about DUROLANE's availability for Cigna patients?

DUROLANE will be offered exclusively to Cigna patients, enhancing its market position.

Who is the Vice President of Bioventus mentioned in the press release?

Tim Donovan is the Vice President of Market Access & Health Economics for Bioventus.